CorMedix CRMD and Puma Biotechnology PBYI are small-cap biotech companies focused on the successful commercialization of their core products as they work to establish leadership within their ...

In this article, we will take a look at some of the small-cap drug manufacturing stocks that are highly favored by hedge funds. On February 16, Franklin Templeton shared its outlook on the ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

Small caps continue to have attractive valuations heading into 2026. Compared to large caps on a relative basis, small caps are significantly cheaper today than they were in most time periods. It is ...

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements ...

The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...

After several years of persistent headwinds, small-cap equities may finally be entering a more supportive phase. Lower interest rates matter disproportionately for small-cap businesses. Compared with ...